General Information of Drug (ID: DMADEHZ)

Drug Name
LY2880070 Drug Info
Synonyms
1375637-35-6; SCHEMBL15124196; BCP32047; EX-A3339; ZINC199531075; LY 2880070 pound>>LY-2880070; (R)-[5-(2-Methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy) -pyrazin-2-yl]-amine; (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine; N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
PubChem CID
56968075
TTD Drug ID
DMADEHZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [3]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [4]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
LY2606368 DM4XMF7 Ovarian cancer 2C73 Phase 2 [6]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [7]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [8]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [10]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [11]
XL844 DMHTG38 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT02632448) A Study of LY2880070 in Participants With Advanced or Metastatic Cancer. U.S. National Institutes of Health.
2 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
3 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
4 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
5 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 National Cancer Institute Drug Dictionary (drug id 730054).
8 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
9 Clinical pipeline report, company report or official report of AstraZeneca (2009).
10 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
11 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
12 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.